Paul D. Rubin - 01 Apr 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Reporting relationship: Chief Medical Officer
Issuer ticker: BIOA
Reported as of: 01 Apr 2026
Net transaction value: -$157,084
SEC form: 4
Accepted by SEC: 03 Apr 2026, 16:07:11 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov A. Goldstein as attorney-in-fact

Key filing fact

Paul D. Rubin filed Form 4 for BioAge Labs, Inc. (BIOA) on 03 Apr 2026.

Key facts

This page summarizes Paul D. Rubin's Form 4 filing for BioAge Labs, Inc. (BIOA).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Apr 2026, 16:07.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$157,084.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001210905 Primary reporting owner

RUBIN PAUL D

Relationship: Chief Medical Officer
Address: C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE
Signature: /s/ Dov A. Goldstein as attorney-in-fact
Signature date: 03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOA transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,437
Change %
Price: $4.11^*
Shares after: 5,437
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

BIOA transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,383
Change %: +62%
Price: $6.57^*
Shares after: 8,820
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

BIOA transaction

Common Stock

Sale

Transaction value: $157,084
Shares: -8,820
Change %: -100%
Price: $17.81
Shares after: 0
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -5,437
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,437
Exercise price: $4.11
Footnotes: F1, F2

BIOA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -3,383
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,383
Exercise price: $6.57
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

Footnote F2

This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.

Footnote F3

The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.